Press Releases
Basulin™ Controlled-Release Insulin is the Subject of a Presentation at the 5th European Symposium on Controlled Drug Delivery
LYON, FRANCE, APRIL 2, 1998. Flamel Technologies S.A. (NASDAQ: FLML) today announced that the Company's Basulin™ controlled-release basal insulin formulation and its underlying Medusa® protein delivery technology were the subject of two poster presentations made yesterday at the 5th European Symposium on Controlled Drug Delivery, held in Noordwijk an Zee in the Netherlands.
The first poster is entitled "In Vivo Profile of Basulin, A New Long-Acting Insulin Formulation With Polyaminoacid Nanoparticles." The Company presented animal data comparing Basulin™ with the two leading long-acting insulins on the market. The studies indicate that Basulin™ results in a significantly flatter pharmacokinetic profile than the comparison insulin products, coupled with a release profile lasting approximately 48 hours compared to 12-16 hours for the commercial formulations. The second presentation, describing the Medusa® protein delivery System, is entitled "Controlled-Release of Insulin From Nanoparticles of Amphiphilic Block Copolyaminoacid." These presentations will be published in an upcoming issue of the Journal of Controlled-Release.
"The Company believes that if the preclinical results with Basulin™ are confirmed in clinical testing, this product should lead to a significant improvement in basal insulin therapy - notably through a better control of glucose levels and fewer injections" commented Dr. Philippe Vivet, Medical Director of Flamel. "We are encouraged by this data and will move to start human clinical trials by the end of this year," said Gérard Soula, Chief Executive Officer of the Company.
Flamel Technologies is engaged in the development of advanced polymer technologies for unique drug delivery and biomaterial applications. The Company is building on its principal technology platforms - the delivery of active ingredients with its Micropump® and Medusa® drug delivery systems, its Agsome™ delivery system for agrochemical active ingredients, its Colcys biomaterial-based medical devices, and photochromic materials for ophtalmic lens products - to meet important unmet medical needs and develop other commercially valuable products.
Agsome™ and Basulin™ are trademarks, and Micropump® and Medusa® are registered trademarks, of Flamel Technologies.
NOTE: This press release contains statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties, including but not limited to the risk that this transaction will not be consummated, the risk associated with the Company's limited history of operations and historic and future losses, and the risk that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, reliance on outside parties and the risks associated with key strategic alliances, and other risks detailed in the Company's filings with the Securities and Exchange Commission.
